Sign in
CompletedPhase 2

PDC-1421 Treatment in Adult Patients With ADHD

Key facts

Who runs it
BioLite, Inc.
Where
San Francisco, United StatesSee the siteAlso in 1 other country, 5 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
99 people enrolled
Started
7 Apr 2022
Ended
8 Apr 2024
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • PDC-1421 Capsule
  • Placebo
Record updated
6 May 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Aged 18-70 years
  • Female subjects of child-bearing potential must test negative to pregnancy and use appropriate birth control method from the beginning of study to the 15 days later after ending of study
  • Subjects must be able to understand and willing to sign informed consent
  • Able to discontinue the use of any psychotropic medications for the treatment of ADHD symptoms at screening
  • Meet strict operational criteria for adult ADHD according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)
  • A total score of 28 or higher of ADHD Rating Scale-Investigator Rated (ADHD-RS-IV) at screening
  • Have a moderate or severe symptom of ADHD with score of 4 or higher in Clinical Global Impression- Severity (CGI-S) at screening

Who cannot take part

  • Have any clinically significant concurrent medical condition (endocrine, renal, respiratory, cardiovascular, hematological, immunological, cerebrovascular, neurological, anorexia, obesity or malignancy) that has become unstable and may interfere with the interpretation of safety and efficacy evaluations
  • Have known serological evidence of human immunodeficiency virus (HIV) antibody
  • Have current of bipolar and psychotic disorders
  • Have a current major depression disorder, obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder, panic disorder and eating disorder (also if treated but not currently symptomatic) NOTE: Comorbid diagnoses identified during screening and baseline are acceptable provided that ADHD is the primary diagnosis and the comorbid diagnoses will not confound study data or impair subject's ability to participate (per the Investigator's judgement and documented in source note)
  • Have any history of a significant suicide attempt, or possess a current risk of attempting suicide, in the investigator's opinion, based on clinical interview and responses provided on the Columbia-Suicide Severity Rating Scale (C-SSRS)
  • Have a history of jailing or imprisonment in the past 6 months due to worsening of symptoms of ADHD
  • Have any clinically significant abnormal laboratory, vital sign, physical examination, or electrocardiogram (ECG) findings at screening that, in the opinion of the investigator, may interfere with the interpretation of safety or efficacy evaluations
  • Have QTc values >450 msec at screening using Fridericia's QTc formula
  • Are pregnant as confirmed by a positive pregnancy test at screening

Where in United States

Also in 1 other country, 5 sites

  • University of California San FranciscoSan Francisco, United States

About the trial

What the trial wants to find out

Part II is a double-blind, randomized, parallel-group, placebo-controlled study. The primary objective of this trial is to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD. The secondary objective is to evaluate the safety of PDC-1421 Capsule in subjects receiving PDC-1421 at various dose levels.

The 3 groups in the trial

  • PlaceboPlacebo, for comparison

    Two placebo capsules thrice daily for 56 days (8 weeks).

  • Low-doseTreatment being tested

    One placebo capsule and 1 PDC-1421 Capsule, thrice daily for 56 days (8 weeks).

    Treatment: PDC-1421 Capsule and Placebo

  • High-doseTreatment being tested

    Two PDC-1421 Capsules thrice daily for 56 days (8 weeks).

    Treatment: PDC-1421 Capsule

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD), Part II
Record updated
6 May 2026